LOS ANGELES--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB: ACTC - News) announced today that principal investigator Dr. Nabil Dib, M.D., M.Sc., FACC, presented results from a 23-patient study of ACTâ€™s myoblast therapy for the treatment of congestive heart failure (CHF) over the weekend at the International Society for Cardiovascular Translational Research (ISCTR) World Symposium in San Diego, CA.
presented the results as a case study of the successful translation of a therapy from scientific research to the bedside.
The results of the study demonstrate long term cell survival in heart failure patients as well as strong quality of life improvements as measured by the New York Heart Association
third party questionnaire, the Minnesota Living with Heart Failure Questionnaire, and the 6 minute walk results (compared to continued deterioration by the control group).
Moreover, ACTâ€™s myoblast trial has been the only cell-based, FDA-approved human clinical trial that has not required the administration of anti-arrhythmic drugs or assist devices, which is in contrast to trials for bone marrow-derived and other adult stem cell therapies.
is an annual meeting for basic and clinical scientist practicing cardiovascular disease research sponsored by the University California, San Diego, Catholic Healthcare West and the International Society for Cardiovascular Translational Research
Dr. Dib is Director, Clinical Cardiovascular Cell Therapy, University of California, San Diego, and Director of Cardiovascular Research of Catholic Health Care Westâ€™s Chandler Regional Hospital and Mercy Gilbert Medical Center near, Phoenix, Arizona.
Dr. Dib enrolled 23 patients at Arizona Heart Institute with poor heart function and congestive heart failure.
â€In this study, we learned that ASM cell transplantation using a minimally invasive catheter system is safe, showed improvement in measures of quality of life, and may have the potential to improve cardiac function and electrical activity,â€ said Dr. Dib
By using a catheter and transplanting ASM cells into scarred tissue, new living muscle can potentially be formed with limited risk to the patient.
Since the transplanted stem cells are harvested from the patientâ€™s own skeletal muscles, the cells are compatible with the body, avoiding possible immune system and tissue compatibility complications.
The procedure poses less risk than surgical procedures because no anesthesia is required and only a small incision is necessary for catheter access.
Patients can be discharged within 24 hours of the procedure.
â€We are honored that the ISCTR chose our myoblast therapy as the centerpiece for discussing how best to translate research from the bench to the bedside,â€ stated William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology, Inc. â€We remain encouraged by the data Dr. Dib presented and believe the positive 12-month data represent another step in our process of initiating a Phase II human clinical trial for our myoblast therapy.